Media headlines about Epizyme (NASDAQ:EPZM) have been trending somewhat positive on Friday, Alpha One Sentiment Analysis reports. The research group, a subsidiary of Accern, identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Epizyme earned a daily sentiment score of 0.18 on Alpha One’s scale. Alpha One also gave media headlines about the biopharmaceutical company an impact score of 68 out of 100, indicating that recent press coverage is likely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Alpha One Sentiment Analysis’s rankings:
- Epizyme : Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO (4-traders.com)
- Epizyme Inc (EPZM) Receives “Buy” Rating from HC Wainwright (americanbankingnews.com)
- How Do Margins Stack up For Epizyme, Inc. (NasdaqGS:EPZM)? – Geneva Journal (genevajournal.com)
- Epizyme (EPZM) Identifies Path Toward Submission for Accelerated … – StreetInsider.com (streetinsider.com)
- Epizyme’s (EPZM) Outperform Rating Reiterated at Wedbush (americanbankingnews.com)
Epizyme (NASDAQ:EPZM) traded up 4.68% during midday trading on Friday, hitting $17.90. The stock had a trading volume of 797,440 shares. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.50. The company’s 50 day moving average price is $16.04 and its 200-day moving average price is $13.24. The stock’s market cap is $1.04 billion.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. Analysts forecast that Epizyme will post ($2.46) EPS for the current fiscal year.
EPZM has been the subject of a number of research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $19.00 price objective (down previously from $26.00) on shares of Epizyme in a report on Saturday, March 11th. Cann reiterated an “outperform” rating and issued a $26.00 price objective on shares of Epizyme in a report on Wednesday, April 12th. Oppenheimer Holdings Inc. initiated coverage on Epizyme in a report on Thursday, April 13th. They issued an “outperform” rating and a $26.00 price objective for the company. CIBC reiterated an “outperform” rating on shares of Epizyme in a report on Thursday, April 13th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Tuesday. Eleven research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $24.88.
In other news, insider Robert A. Copeland sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $17.44, for a total value of $87,200.00. Following the completion of the transaction, the insider now directly owns 36,538 shares of the company’s stock, valued at approximately $637,222.72. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew E. Singer sold 2,013 shares of the business’s stock in a transaction on Friday, March 31st. The stock was sold at an average price of $17.09, for a total value of $34,402.17. Following the completion of the transaction, the chief financial officer now directly owns 36,175 shares of the company’s stock, valued at $618,230.75. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,013 shares of company stock valued at $203,402. Corporate insiders own 25.40% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with MarketBeat.com's FREE daily email newsletter.